Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | terminated | Phase 3 | 174 | Abnoba GmbhINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT04149574 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)(CheckMate 7G8) | terminated | Phase 3 | 13 | Bristol-Myers SquibbINDUSTRY | 16 | Sep 16, 2025 |
| clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | terminated | Phase 3 | 62 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | terminated | Phase 3 | 118 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 3 | 47 | Spectrum Pharmaceuticals, IncINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT01200992 | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer(EMBARC-RF) | terminated | Phase 3 | 84 | Bioniche Life Sciences Inc.INDUSTRY | 6 | Aug 24, 2017 | clinicaltrials |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | terminated | Phase 3 | 521 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 8, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | terminated | Phase 3 | 66 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Dec 13, 2016 | clinicaltrials |
| NCT00974818 | Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients | terminated | Phase 3 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00384891 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | terminated | Phase 3 | 190 | Medical Enterprises Europe B.V.INDUSTRY | 4 | Oct 7, 2014 | clinicaltrials |
| NCT00042887 | Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | terminated | Phase 3 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00237575 | Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | terminated | Phase 3 | 100 | University of KentuckyOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00003824 | S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer | terminated | Phase 3 | 114 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 9, 2012 | clinicaltrials |
| NCT00191477 | Instillation of Gemcitabine in Patients With Superficial Bladder Cancer | terminated | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials